TL;DR: A 2026 placebo-controlled study in Human Psychopharmacology: Clinical and Experimental found that ebselen did not meaningfully reduce motor impulsivity, reflection impulsivity, delay discounting, or emotion-recognition outcomes in 130 healthy adults. Key Findings 130 adults analyzed: The double-blind study compared 66 adults assigned to ebselen with 64 assigned to placebo. 1800 mg over 2 days: …
TL;DR: A 2026 review in Current Opinion in Psychiatry found that earlier clozapine use in schizophrenia, especially after early nonresponse or relapse, was linked to better relapse prevention and stronger response rates than repeated nonclozapine antipsychotic trials. Key Findings Relapse prevention improved: Switching to clozapine after first relapse was associated with a 34% lower subsequent …
TL;DR: A 2026 Phase I study in CNS Drugs found that a 400 mg powdered cannabidiol (CBD) formulation reached peak blood levels faster than oil-based Epidyolex, especially after a high-fat meal, while both products were generally well tolerated in healthy adults. Key Findings Four-way crossover trial: Researchers gave 32 healthy adults single 400 mg doses …
TL;DR: A 2026 case study in Neurological Sciences described 2 Tourette syndrome patients who developed oculogyric crisis, a sustained upward eye-rolling dystonia, after aripiprazole was increased to 20-30 mg/day, with both cases resolving after dose reduction. Key Findings 2 Tourette cases: The report described 2 female patients, ages 16 and 22, treated with aripiprazole for …
TL;DR: A 2026 randomized single-blind trial in BMC Psychiatry found that a one-day lithium carbonate loading dose plus quetiapine reduced acute manic symptoms in bipolar I disorder more than standard slow-titration lithium plus quetiapine over 14 days. Key Findings 60 inpatients randomized: Adults with bipolar I disorder in acute mania, all meeting DSM-5 criteria and …
TL;DR: A 2026 study in Molecular Neurobiology found that Antrodia cinnamomea, a medicinal fungus extract, worked best when carried on citrate-stabilized silver nanoparticles in cell and rat models of Parkinson’s-like dopamine injury. Key Findings 6-OHDA created Parkinson’s-like injury: The toxin reduced SH-SY5Y cell viability and produced unilateral dopamine-system damage in rats. Combination treatment was strongest: …
TL;DR: A 2026 systematic review and meta-analysis in Acta Neuropsychiatrica found no clear evidence that parenteral clomipramine is better than oral clomipramine for depression or obsessive-compulsive disorder, with low or very low certainty across the main randomized-trial evidence. Key Findings 4,973 publications screened: The review identified 14 randomized controlled trials relevant to parenteral clomipramine in …
TL;DR: A 2026 study in Drug Design, Development and Therapy validated liquid chromatography-tandem mass spectrometry (LC-MS/MS), a high-specificity lab method, to screen serum for 77 neuropsychiatric drugs and then applied it to 1,021 clinical specimens over 3 years. Key Findings 77 drugs screened: Researchers developed a serum LC-MS/MS method for simultaneous qualitative identification of neuropsychiatric …
TL;DR: A 2026 human laboratory study in Drug and Alcohol Dependence Reports found that naltrexone/bupropion did not change whether people with binge-eating disorder started eating preferred snacks, but it reduced how many calories they ate once they began. Key Findings Naltrexone/bupropion trial included 50 adults: Participants came from a randomized trial of naltrexone/bupropion, including 23 …
TL;DR: A 2026 mouse study in Proceedings of the National Academy of Sciences found that deleting or inhibiting PTP1B improved memory behavior, reduced amyloid-beta burden, and pushed microglia toward an amyloid-clearing state. Key Findings Memory behavior improved: APP/PS1 mice lacking PTP1B performed better in novel object recognition and Morris water maze tests; the PTP1B inhibitor …
